Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H or CN; and wherein R1 R2 R3 and R4 are as described herein. A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic...

Disclosed is the use of a DPPIV inhibitor (such as glutaminyl thiazolidine based DPIV inhibitors sitagliptin vildagliptin saxagliptin denagliptin or alogliptin) in combination with metformin or a thiazolidinedione (such as troglitazone ciglitazone pioglitazone englitazone or rosiglitazone) in the manufacture of a medicament for the treatment of type 2 diabetes in a human wherein the DPIV inhibitor in combination with metformin or a thiazolidinedione is a first-line therapy for the treatment of t...

The present invention relates to methods and compositions for the treatment of Myotonic Dystrophy type 1 (DM1) with an AMPK activator .

PROBLEM TO BE SOLVED: To provide an OATP-R gene expression-enhancing composition that ensures higher safety and exhibits an OATP-R gene expression-enhancing action. SOLUTION: The OATP-R gene expression-enhancing composition comprises an angiotensin II receptor-inhibiting substance (ARB) and/or a glitazone-based hypoglycemic substance. As the ARB there can be preferably exemplified losartan candesartan candesartan cilexetil olmesartan valsartan irbesartan eprosartan telmisartan EXP3174 (a metabo...

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin lovastatin simvastatin fluvastatin rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone pioglitazone englitazone BRL-49653 5-(4-ä2-Ä1-(4-2'-pyridylphenyl)ethylideneaminooxyÜ-ethoxyübenzylüthiaz olidine-24-dione 5-ä4-(5-methoxy-3-methylimidazoÄ54-bÜpyridin-2-yl-methoxy)benzylüthia zolidine-24-dione or its hydrochloride 5-Ä4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzylÜthi...

PROBLEM TO BE SOLVED: To obtain the subject inhibitor useful as a preventive and therapeutic agent for diseases in which promotion of apoptosis concern e.g. viral diseases neurodegenerative diseases myelodysplastic diseases isthemic cardiopathy or liver disease by including a specific compound.SOLUTION: This inhibitor is obtained by including a compound of the formula {R is a (substituted)hydrocarbon or a heterocyclic ring; Y is a group of the formula CO CH(OH) or NR(sup 3) [R(sup 3) is a (subst...

Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H; and wherein R 1 R 2 R 3 and R 4 are as described herein.A method is also provided for treating diabetes and related diseases especially Type II diabetes and other diseases as set out herein employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabeti...

This invention provides a process for reducing an exocyclic double bond at the 5-position of a thiazolidinedione moiety of a thiazolidinedione precursor comprising the steps of: a) preparing a solution or suspension of the thiazolidinedione precursor in a non-ether solvent medium with a base and b) combining the solution or suspension with a dithionite source. Preferred solvent media include aqueous NN-dimethylformamide. Sodium dithionite is a preferred dithionite source. In particular the appli...

Insulin sensitivity enhancers such as troglitazone have the ability to tre at and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout urinary calculus hyperuricemic nephropathy and Lesch-Nyha n syndrome.